Document Detail


Lipid status, anti-oxidant enzyme defence and haemoglobin content in the blood of long-term clozapine-treated schizophrenic patients.
MedLine Citation:
PMID:  19962416     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: Despite clozapine's unique effectiveness in patients with schizophrenia, a number of adverse effects have been recognised including abnormalities in lipid and glucose metabolisms. A high clozapine level in red blood cells (RBCs) and disturbed anti-oxidant enzyme activities in blood from schizophrenic patients prompted us to investigate lipid status and anti-oxidant enzyme defence in the blood of chronic schizophrenic patients on long-term clozapine therapy. METHODS: Plasma lipids, RBC anti-oxidant enzyme activities and haemoglobin (Hb) content were measured using established procedures in a group of eighteen chronically-medicated (average 630 days of therapy) schizophrenic patients receiving clozapine (average dose of 295 mg/day) and data were compared with those from a group of eighteen well-matched normal controls. RESULTS: Significantly higher levels of plasma triglycerides (by 47%, p<0.01) and total cholesterol and phospholipids (by 8% and 11%, respectively p<0.05) in patients were found. CuZn-superoxide dismutase (SOD1) activity was markedly higher (by 35%, p<0.001) while selenium-dependent glutathione peroxidase (GSH-Px1) activity was markedly lower (by 41%, p<0.001) in patients. In addition, metHb and HbA1c levels in patients were significantly higher (by 58% and 25%, respectively p<0.001). SOD1 activity was negatively correlated (p<0.001) to GSH-Px1 activity in patients. CONCLUSIONS: The findings support the view that ongoing oxidative stress may be a mechanism by which clozapine induces some adverse effects that increase the risk of diabetes and metabolic syndrome. If valid, this would indicate that in parallel with long-term clozapine treatment, schizophrenic patients could be encouraged to make some lifestyle changes to limit the detrimental effects of the medication.
Authors:
Cedo Miljevic; Milan Nikolic; Aleksandra Nikolic-Kokic; David R Jones; Vesna Niketic; Dusica Lecic-Tosevski; Mihajlo B Spasic
Related Documents :
22246146 - Ct colonography without cathartic preparation: positive predictive value and patient ex...
18261886 - Cerebrospinal fluid d-serine and glycine concentrations are unaltered and unaffected by...
1798826 - Deficit syndrome in older schizophrenic patients.
9000316 - The stroop effect in schizophrenic patients.
7363686 - Atenolol in hypertension: a cardioselective drug.
7775506 - Acute pseudo-obstruction in critically ill patients with burns.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2009-12-03
Journal Detail:
Title:  Progress in neuro-psychopharmacology & biological psychiatry     Volume:  34     ISSN:  1878-4216     ISO Abbreviation:  Prog. Neuropsychopharmacol. Biol. Psychiatry     Publication Date:  2010 Mar 
Date Detail:
Created Date:  2010-02-22     Completed Date:  2010-05-13     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8211617     Medline TA:  Prog Neuropsychopharmacol Biol Psychiatry     Country:  England    
Other Details:
Languages:  eng     Pagination:  303-7     Citation Subset:  IM    
Copyright Information:
Copyright 2009 Elsevier Inc. All rights reserved.
Affiliation:
Institute of Mental Health, Belgrade, Serbia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Anthropometry / methods
Antipsychotic Agents / pharmacology*,  therapeutic use
Body Composition / drug effects
Body Mass Index
Catalase / blood
Clozapine / pharmacology*,  therapeutic use
Erythrocytes / drug effects*,  enzymology
Female
Glutathione Peroxidase / blood
Glutathione Reductase / blood
Hemoglobins / metabolism*
Humans
Lipids / blood*
Longitudinal Studies
Male
Schizophrenia / blood*,  drug therapy
Superoxide Dismutase / blood
Chemical
Reg. No./Substance:
0/Antipsychotic Agents; 0/Hemoglobins; 0/Lipids; 5786-21-0/Clozapine; EC 1.11.1.6/Catalase; EC 1.11.1.9/Glutathione Peroxidase; EC 1.15.1.1/Superoxide Dismutase; EC 1.8.1.7/Glutathione Reductase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A review of the UK methodology used for monitoring cigarette smoke yields, aspects of analytical dat...
Next Document:  KMUP-1 attenuates serum deprivation-induced neurotoxicity in SH-SY5Y cells: Roles of PKG, PI3K/Akt a...